Literature DB >> 10823399

A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler.

R West1, P Hajek, J Foulds, F Nilsson, S May, A Meadows.   

Abstract

RATIONALE: Nicotine replacement therapy (NRT) in varying forms is becoming widely used. Clinicians, therapists and regulatory authorities are interested in the abuse liability and dependence potential of the different forms.
OBJECTIVES: To compare the abuse liability and dependence potential of nicotine gum, transdermal patch, spray and inhaler.
METHODS: 504 male and female smokers seeking help with stopping smoking were randomly allocated to the four products. Measures were taken at the designated quit date, then 1 week, 4 weeks, 12 weeks and 15 weeks later. Smokers were advised to use the product for up to 12 weeks. Those still using the product at the 12-week visit were advised to cease use by week 14. Measures included: pleasantness and satisfaction ratings at weeks 1 and 4 (used as a marker of abuse liability); ratings of feeling dependent on NRT at weeks 1, 4, 12 and 15 (used as a marker of subjective dependence); mood and physical symptoms ratings at weeks 12 and 15 (the change being used to assess physical dependence on NRT), continued usage of NRT at week 15 (used as an marker of behavioural dependence).
RESULTS: Average ratings of pleasantness were low. The nicotine patch was rated as less unpleasant to use than all other products. There were no significant differences between the products in terms of satisfaction or subjective dependence except at week 15 when no patch users rated themselves as dependent. Continued use of NRT at week 15 was related to rate of delivery of nicotine from the products - 2% for patch, 7% for gum and inhaler, 10% for spray (P<0.05 for linear association). Among those

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823399     DOI: 10.1007/s002130000382

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  53 in total

Review 1.  Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies.

Authors:  Asti Jackson; Ben Grobman; Suchitra Krishnan-Sarin
Journal:  Neuropharmacology       Date:  2020-06-24       Impact factor: 5.250

2.  Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample.

Authors:  S Shiffman; J R Hughes; J L Pillitteri; S L Burton
Journal:  Tob Control       Date:  2003-09       Impact factor: 7.552

3.  How Intravenous Nicotine Administration in Smokers Can Inform Tobacco Regulatory Science.

Authors:  Kevin P Jensen; Elise E DeVito; Mehmet Sofuoglu
Journal:  Tob Regul Sci       Date:  2016-10-01

4.  Markov model of smoking cessation.

Authors:  Peter R Killeen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-20       Impact factor: 11.205

5.  Electronic nicotine delivery systems: a research agenda.

Authors:  Jean-François Etter; Chris Bullen; Andreas D Flouris; Murray Laugesen; Thomas Eissenberg
Journal:  Tob Control       Date:  2011-03-17       Impact factor: 7.552

Review 6.  Over-the-counter nicotine replacement therapy: can its impact on smoking cessation be enhanced?

Authors:  Nancy Amodei; R J Lamb
Journal:  Psychol Addict Behav       Date:  2008-12

Review 7.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 8.  Nicotine chemistry, metabolism, kinetics and biomarkers.

Authors:  Neal L Benowitz; Janne Hukkanen; Peyton Jacob
Journal:  Handb Exp Pharmacol       Date:  2009

Review 9.  Effect of smokeless tobacco (snus) on smoking and public health in Sweden.

Authors:  J Foulds; L Ramstrom; M Burke; K Fagerström
Journal:  Tob Control       Date:  2003-12       Impact factor: 7.552

10.  Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration.

Authors:  Xiu Liu
Journal:  Psychopharmacology (Berl)       Date:  2013-05-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.